http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 08:00:27 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html <p>Aura Biosciences Inc. (NASDAQ: AURA) completed enrollment of 108 patients in its Phase 3 CoMpass trial evaluating belzupacap sarotalocan as a treatment for early choroidal melanoma, according to a company statement.</p> <p>The trial represents the first registration-enabling study for patients with early choroidal melanoma. The randomized Phase 3 study compares bel-sar versus sham control in the frontline setting under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.</p> <p>Topline data from the 15-month primary endpoint are expected in the second half of 2027, the company said.</p> <p>"We believe bel-sar has the potential to become the first approved frontline, vision-preserving therapy http://www.streetinsider.com/FDA/Aura+Biosciences+completes+enrollment+in+phase+3+choroidal+melanoma+trial/26579476.html Mon, 01 Jun 2026 08:00:27 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html <p align="center"><em>Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial</em></p> <p align="center"><em>Topline data from the 15-month primary endpoint expected in the second half of 2027 </em></p> <p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0uYaLHx4-fiq13DqE5n2wDRDHpDahXmnHsT-v_u5O6HFeOS_JfIZsJZhugsnHjRB4mM5M8DRtKVcjF6uuPMsMldzWJwK4-8mskre4bsyKuhp6WNH2J4pAu2QdJ7JW2Hl" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Enrollment+Completion+in+Phase+3+CoMpass+Trial+of+Bel-sar+in+Early+Choroidal+Melanoma/26579434.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 A.31066700 AURA O.07116383 O.20026344 O.22422661 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+May+19++Filed+by%3A+Holles+Natalie+C./26522309.html si-local-file:///var/storage/secattach/20260519/26522309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+May+19++Filed+by%3A+Holles+Natalie+C./26522309.html Tue, 19 May 2026 17:00:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+May+19++Filed+by%3A+Holles+Natalie+C./26522309.html si-local-file:///var/storage/secattach/20260519/26522309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aura+Biosciences%2C+Inc.++++For%3A+May+19++Filed+by%3A+Holles+Natalie+C./26522309.html Tue, 19 May 2026 17:00:00 -0400 AURA O.07116383 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html <p align="justify">BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0Oi_icZE31LdFVNj18KIKH00SfIHMrsM7j1IbOz7JxHMebHCvFeLGykvYQF1byrDOx0ZhZzjJRrVQFt2qh35B5VHSje4IWZ2711XjMc1-AOpzeThysMi_vfWl0OOVECu" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles’ offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html Tue, 19 May 2026 16:50:00 -0400 AURA O.07116383 http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html <p align="justify">BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0Oi_icZE31LdFVNj18KIKH00SfIHMrsM7j1IbOz7JxHMebHCvFeLGykvYQF1byrDOx0ZhZzjJRrVQFt2qh35B5VHSje4IWZ2711XjMc1-AOpzeThysMi_vfWl0OOVECu" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles’ offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p http://www.streetinsider.com/Press+Releases/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html Tue, 19 May 2026 16:50:00 -0400 AURA O.07116383 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html <p align="justify">BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0Oi_icZE31LdFVNj18KIKH00SfIHMrsM7j1IbOz7JxHMebHCvFeLGykvYQF1byrDOx0ZhZzjJRrVQFt2qh35B5VHSje4IWZ2711XjMc1-AOpzeThysMi_vfWl0OOVECu" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles’ offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html Tue, 19 May 2026 16:50:00 -0400 AURA O.07116383 http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html <p align="justify">BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=0Oi_icZE31LdFVNj18KIKH00SfIHMrsM7j1IbOz7JxHMebHCvFeLGykvYQF1byrDOx0ZhZzjJRrVQFt2qh35B5VHSje4IWZ2711XjMc1-AOpzeThysMi_vfWl0OOVECu" rel="nofollow" target="_blank">Aura Biosciences, Inc.</a> (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles’ offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p http://www.streetinsider.com/Globe+Newswire/Aura+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26522171.html Tue, 19 May 2026 16:50:00 -0400 AURA O.07116383 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Aura+Biosciences%2C+Inc.+++++++++++++++/26521766.html si-local-file:///var/storage/secattach/20260519/26521766.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Aura+Biosciences%2C+Inc.+++++++++++++++/26521766.html Tue, 19 May 2026 16:32:00 -0400 AURA O.07116383